Quantcast

Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC

Research paper by Yi-Fu Hou, Yong-Gang Wei, Jia-Yin Yang, Tian-Fu Wen, Ming-Qing Xu, Lu-Nan Yan, Bo Li

Indexed on: 17 Aug '16Published on: 17 Aug '16Published in: Hepatobiliary & Pancreatic Diseases International



Abstract

Combined hepatectomy and radiofrequency ablation (RFA) provides an additional treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) who are conventionally deemed unresectable. This study aimed to analyze the outcome of this combination therapy by comparing it with transarterial chemoembolization (TACE).